<< Back To Search

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06057402
Age 18 +
Sex Both
Phase Phase 4
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of therapies that have not been widely tested together before.
  • Participants will receive personalized care based on their individual health needs and responses to the treatment.
  • The study aims to evaluate how effective this combination is in managing the disease and improving quality of life.
  • Patients will be closely monitored throughout the study to track their progress and any side effects.
  • This research is being conducted at multiple centers, allowing for a diverse group of participants and more comprehensive results.
Overall, this study is significant because it seeks to provide a more tailored treatment option that could lead to better management of the disease and potentially improve survival rates for patients.
Third Opinion AI Generated Synopsis

Trial Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: